查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1597734

皮下免疫球蛋白市场：按适应症、最终用户划分 - 全球预测 2025-2030

Subcutaneous Immunoglobulin Market by Indication (Primary Immunodeficiencies, Secondary Immunodeficiencies), End-User (Homecare Settings, Hospitals & Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年皮下免疫球蛋白市场价值为94.7亿美元，预计到2024年将达到104.6亿美元，复合年增长率为10.82%，到2030年将达到194.6亿美元。

皮下免疫球蛋白（SCIg）是指透过皮下注射施用免疫球蛋白的医学疗法，主要用于原发性免疫力缺乏疾病和某些自体免疫疾病的患者。这项需求源自于维持足够的免疫球蛋白水平的需要，这对于免疫系统受损的患者抵抗感染疾病至关重要。应用范围从常规家庭输液（比静脉注射对患者更方便）到医院环境（主要针对免疫力缺乏的患者）。最终用途包括医疗保健设施、居家照护场所、专科诊所等。免疫不全症盛行率的上升、SCIg 製剂的进步以及患者对家庭治疗的偏好的增加对市场成长产生了显着影响。此外，持续的研究和开发正在创造创新的输送机制，例如无针系统，这些机制正在引起市场关注。然而，潜在的副作用、高治疗成本和监管挑战等限制因素可能会阻碍市场成长。此外，不同地区患者对治疗方案的认识并不一致，增加了挑战。最近的潜在商机包括将 SCIg 的应用扩展到新的治疗领域以及加强开拓市场的销售网络。抓住这些机会的建议包括投资教育和意识计划、与医疗保健提供者合作以及游说有利的报销政策。改进的输送装置和更稳定的免疫球蛋白配方等创新是有希望促进业务成长的研究领域。此外，用于病患监测和管理的数位平台可以提供策略优势。 SCIg 市场的特点是竞争格局激烈，多个主要企业不断投资于技术进步。需要策略敏捷性来驾驭监管、患者倡导和竞争格局，同时专注于技术和治疗创新以实现持续成长。

主要市场统计
基准年[2023] 94.7亿美元
预测年份 [2024] 104.6亿美元
预测年份 [2030] 194.6亿美元
复合年增长率（%） 10.82%

市场动态：快速发展的皮下免疫球蛋白市场的关键市场洞察

供需的动态交互作用正在改变皮下免疫球蛋白市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球自体免疫疾病盛行率上升
    • 仿单标示外使用中皮下免疫球蛋白的使用增加
    • 生技和製药公司增加对研发项目的投资
  • 市场限制因素
    • 皮下免疫球蛋白治疗相关的巨额费用
  • 市场机会
    • 增加政府资助和对皮下免疫球蛋白治疗的认识
    • 皮下免疫球蛋白给药的创新
  • 市场挑战
    • 严格的政府法规和治疗副作用的高风险

波特的五力：驾驭皮下免疫球蛋白市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解皮下免疫球蛋白市场的外部影响

外部宏观环境因素在塑造皮下免疫球蛋白市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解皮下免疫球蛋白市场的竞争格局

皮下免疫球蛋白市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵皮下免疫球蛋白市场供应商的绩效评估

FPNV 定位矩阵是评估皮下免疫球蛋白市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划皮下免疫球蛋白市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，皮下免疫球蛋白市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球自体免疫疾病的盛行率上升
      • 在仿单标示外适应症中增加皮下免疫球蛋白的使用
      • 生技和製药公司增加对研发项目的投资
    • 抑制因素
      • 皮下免疫球蛋白治疗的庞大费用
    • 机会
      • 增加政府资助并提高对使用皮下免疫球蛋白治疗的认识
      • 皮下免疫球蛋白管理的创新
    • 任务
      • 严格的政府法规和治疗副作用的高风险
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章皮下免疫球蛋白市场依适应症分类

  • 原发性免疫力缺乏
  • 继发性免疫力缺乏缺陷

第七章皮下免疫球蛋白市场：依最终用户分类

  • 家庭护理设置
  • 医院/诊所

第八章北美和南美皮下免疫球蛋白市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太皮下免疫球蛋白市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲皮下免疫球蛋白市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Biotest AG by Grifols SA
  • CSL Behring
  • Kedrion Biopharma Inc.
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • The Bio Products Laboratory
Product Code: MRR-FF012EDC38B2

The Subcutaneous Immunoglobulin Market was valued at USD 9.47 billion in 2023, expected to reach USD 10.46 billion in 2024, and is projected to grow at a CAGR of 10.82%, to USD 19.46 billion by 2030.

Subcutaneous immunoglobulin (SCIg) refers to a medical therapy involving the administration of immunoglobulins via subcutaneous injection, primarily deployed in patients with primary immunodeficiency diseases and certain autoimmune disorders. Its necessity arises from the need to maintain adequate immunoglobulin levels, which are vital to fighting infections in patients with compromised immune systems. The application scope extends from regular home-based infusions, thereby offering patients greater convenience compared to intravenous routes, to hospital settings, primarily serving immunocompromised individuals. End-use segments include healthcare facilities, homecare settings, and specialty clinics. Market growth is significantly influenced by the rising prevalence of immunodeficiency disorders, advancements in SCIg formulations, and increasing patient preference for home-based treatments. Additionally, ongoing research and development yield innovative delivery mechanisms, such as needleless systems, which capture market attention. However, the market faces limitations from potential side effects, high costs of treatment, and regulatory challenges, which could hinder growth. Moreover, patient awareness regarding treatment options remains inconsistent across regions, adding to the challenges. The latest potential opportunities include expanding SCIg applications into new therapeutic areas and enhancing distribution networks to untapped markets. Recommendations to capture these opportunities include investment in education and awareness programs, partnerships with healthcare providers, and lobbying for favorable reimbursement policies. Innovations such as improving delivery devices and formulating more stable immunoglobulin preparations are promising areas of research for business growth. Furthermore, digital platforms for patient monitoring and management could present a strategic advantage. The SCIg market is characterized by a competitive landscape with several key players constantly investing in technological advancements. It requires strategic agility to navigate regulatory landscapes, patient advocacy, and competitive pressures while focusing on technological and therapeutic innovations for sustained growth.

KEY MARKET STATISTICS
Base Year [2023] USD 9.47 billion
Estimated Year [2024] USD 10.46 billion
Forecast Year [2030] USD 19.46 billion
CAGR (%) 10.82%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Subcutaneous Immunoglobulin Market

The Subcutaneous Immunoglobulin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the prevalence of autoimmune disorders globally
    • Increasing usage of subcutaneous immunoglobulin in off-label indications
    • Growing investments in R&D programs by biotechnology and pharmaceutical companies
  • Market Restraints
    • Huge cost associated with subcutaneous immunoglobulin treatment
  • Market Opportunities
    • Rising government funding and increasing awareness about the usage of subcutaneous immunoglobulin treatment
    • Innovations in the administration of subcutaneous immunoglobulin
  • Market Challenges
    • Stringent government regulations and high risk of the side effects of the treatment

Porter's Five Forces: A Strategic Tool for Navigating the Subcutaneous Immunoglobulin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Subcutaneous Immunoglobulin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Subcutaneous Immunoglobulin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Subcutaneous Immunoglobulin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Subcutaneous Immunoglobulin Market

A detailed market share analysis in the Subcutaneous Immunoglobulin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Subcutaneous Immunoglobulin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Subcutaneous Immunoglobulin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Subcutaneous Immunoglobulin Market

A strategic analysis of the Subcutaneous Immunoglobulin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Subcutaneous Immunoglobulin Market, highlighting leading vendors and their innovative profiles. These include Biotest AG by Grifols S.A., CSL Behring, Kedrion Biopharma Inc., Octapharma AG, Takeda Pharmaceutical Company Limited, and The Bio Products Laboratory.

Market Segmentation & Coverage

This research report categorizes the Subcutaneous Immunoglobulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Primary Immunodeficiencies and Secondary Immunodeficiencies.
  • Based on End-User, market is studied across Homecare Settings and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence of autoimmune disorders globally
      • 5.1.1.2. Increasing usage of subcutaneous immunoglobulin in off-label indications
      • 5.1.1.3. Growing investments in R&D programs by biotechnology and pharmaceutical companies
    • 5.1.2. Restraints
      • 5.1.2.1. Huge cost associated with subcutaneous immunoglobulin treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising government funding and increasing awareness about the usage of subcutaneous immunoglobulin treatment
      • 5.1.3.2. Innovations in the administration of subcutaneous immunoglobulin
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and high risk of the side effects of the treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Subcutaneous Immunoglobulin Market, by Indication

  • 6.1. Introduction
  • 6.2. Primary Immunodeficiencies
  • 6.3. Secondary Immunodeficiencies

7. Subcutaneous Immunoglobulin Market, by End-User

  • 7.1. Introduction
  • 7.2. Homecare Settings
  • 7.3. Hospitals & Clinics

8. Americas Subcutaneous Immunoglobulin Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Subcutaneous Immunoglobulin Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Subcutaneous Immunoglobulin Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Biotest AG by Grifols S.A.
  • 2. CSL Behring
  • 3. Kedrion Biopharma Inc.
  • 4. Octapharma AG
  • 5. Takeda Pharmaceutical Company Limited
  • 6. The Bio Products Laboratory

LIST OF FIGURES

  • FIGURE 1. SUBCUTANEOUS IMMUNOGLOBULIN MARKET RESEARCH PROCESS
  • FIGURE 2. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. SUBCUTANEOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SUBCUTANEOUS IMMUNOGLOBULIN MARKET DYNAMICS
  • TABLE 7. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM SUBCUTANEOUS IMMUNOGLOBULIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. SUBCUTANEOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. SUBCUTANEOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2023